Annovis Bio, Inc. (NYSE: ANVS) received U.S. Patent No. 12,582,632 B2 on April 2 2026, covering the prevention and treatment of neurological injuries caused by brain infections using buntanetap or related compounds. The patent protects the use of the drug for both preventive and therapeutic purposes and will expire in 2044.
The new intellectual‑property protection expands Annovis’s portfolio into a novel therapeutic area, potentially broadening the commercial reach of its lead candidate, buntanetap, beyond Alzheimer’s and Parkinson’s disease. By securing this patent, Annovis strengthens its competitive moat and may enhance its attractiveness to future partners or investors.
Annovis remains a pre‑revenue company, reporting a net loss of $10.4 million for Q1 2026 versus $6.9 million a year earlier, and a net loss per share of $1.40 for fiscal 2025 compared with $2.02 in fiscal 2024. Cash and cash equivalents stood at $19.5 million as of December 31 2025, providing funding through the third quarter of 2026.
President and CEO Maria Maccecchini said, “This patent is an important addition to our growing intellectual property estate, and it underscores our commitment to protecting buntanetap’s potential across every avenue where it may benefit patients.” She added, “Alzheimer’s is an extraordinarily complex disease, and it is essential to understand all possible variables and factors involved in its initiation and progression. There is a clear need to identify methods of treating and preventing neurodegeneration resulting from the overexpression of proteins that occur during microbial and viral infections, and this patent positions us to address exactly that.”
The announcement was well received by investors, with an insider purchase of 713,800 shares reported on April 3, valued at $1.498 million, indicating confidence in the company’s direction.
In addition to the patent, Annovis is advancing buntanetap through Phase 3 trials for Alzheimer’s and Parkinson’s disease, and it launched a pivotal Phase 3 trial in early Alzheimer’s in February 2025. The company also announced a partnership with NeuroRPM to enhance Parkinson’s disease clinical trial monitoring using artificial intelligence, further supporting its neurodegeneration platform.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.